The purpose of this study is to investigate the familial response to Methylphenidate treatment (Ritalin IR) in two aspects: ADHD symptom's improvement and side-effects development.
Attention Deficit/Hyperactivity Disorder (ADHD) is very prevalent and tends to continue from childhood to adult life. It's heritability is 76%. It was found that there is a greater ADHD prevalence in first-degree families of ADHD subjects- 4-6 times more than the general population. Pharmacological treatment is the first line treatment today in ADHD, in children and adults, and Methylphenidate (specially Ritalin IR) is the first medication given for the disorder. The study includes couples of first-degree family members, both diagnosed with ADHD. Subjects will receive Ritalin IR for 4 weeks and undergo several psychiatric and cognitive questionnaires at each time of the follow-up meeting (a total of 3).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Duration of treatment- 4 weeks. Dosage- up to 3 times/day. * Ages 6-12, up to 25Kg - 35mg maximum per day. * Ages 6-12, above 25Kg - 50mg maximum per day. * Ages 12-65, above 25Kg - 80mg maximum per day.
ADHD Medical Clinic, Child and Adolescent Psychiatry Unit, Sheba Medical Center
Ramat Gan, Israel
Clinical Global Impression-Improvement scale
Time frame: CGI scale score at 4 weeks <=2
overall ADHD-Rating Scale (ADHD-RS) score
Time frame: change from baseline in ADHD-RS at 2 weeks (reducing >30%), change from baseline in ADHD-RS at 4 weeks (reducing >30%)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.